resveratrol has been researched along with Long QT Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, L; Li, B; Li, F; Liu, Y; Shi, Y; Wang, J; Yan, M | 1 |
| Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Kochhäuser, S; Reinke, F; Wasmer, K; Wolfes, J | 1 |
| Balulad, SS; Bennett, JA; Keller, RS; Rezk, YA | 1 |
3 other study(ies) available for resveratrol and Long QT Syndrome
| Article | Year |
|---|---|
Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism.
Topics: Action Potentials; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ERG1 Potassium Channel; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Lysosomes; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques; Proteolysis; Resveratrol; Stilbenes; Terfenadine | 2017 |
Divergent antiarrhythmic effects of resveratrol and piceatannol in a whole-heart model of long QT syndrome.
Topics: Animals; Anti-Arrhythmia Agents; Female; Heart; Isolated Heart Preparation; Long QT Syndrome; Rabbits; Resveratrol; Stilbenes; Treatment Outcome | 2017 |
Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bradycardia; Cardiotonic Agents; Cell Division; Cell Survival; Cells, Cultured; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Humans; Long QT Syndrome; Mice; Myocytes, Cardiac; Ovarian Neoplasms; Rats; Resveratrol; Stilbenes; Uterine Neoplasms | 2006 |